ENETS Annual Conferences
ENETS held its 10th Annual Conference in Barcelona, 6-8 March 2013. To mark a decade since ENETS foundation, Chairman Kjell Öberg held a keynote talk surveying the importance of the Society and its accomplishments over the years. The conference also featured an expanded Mee the Professor program, lectures on histopathology, clinical trials, lung NETs, rare turmos and surgery, as well as abstract sessions and a postgraduate course which has become extremely popular since it was first offered in Copenhagen in 2012. To view the complete Barcelona program, please click here.
The 8th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease was held 9-11 March 2011, in Lisbon, Portugal. The conference set a record in terms of the number of participants - 1,660 - and also the number of abstracts received: 172. To see the complete conference program, please click here.
The 7th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease was held 11-12 March 2010 in Berlin, Germany. The conference drew a record 1,300 participants and featured nearly 150 submitted abstracts. To view the conference program, please click here. This international conference was endorsed by the European Accreditation Council for Continuing Medical Education with 12 points.
The 5th Annual ENETS Conference was held 6-8 March 2008 in Paris. The conference attracted 902 participants from around 55 countries.
Lectures on evaluating the updated ENETS Guidelines and TNM classification system kicked off the conference.
They were followed by sessions on animal models in NET disease; hereditary endocrine tumors; thoracic NET; test systems for new therapies for NETs and clinical implications; and novel therapies.
Two abstract sessions, one for clinical research and one for basic science, were also part of the conference. The Paris conference saw a record number of abstracts received, as well: 130.
The 4th Annual ENETS Conference was held 15-17 March 2007 in Barcelona. The conference drew around 800 participants from 50 countries, and included sessions on the ENETS Consensus Guidelines; new developments in rare hereditary diseases associated with endocrine tumors and in the imaging of NET; NET networks in Asia and South America; surgery of NETs and new therapies and clinical trials.
Over 90 abstracts, in the categories of basic science and clinical research, were submitted for review.
The 3rd Annual ENETS Conference, which was held in Prague, Czech Republic, 22-24 March attracted 706 scientists from nearly 40 countries.
The conference included lectures on the topics tumor profiling, angiogenesis, receptors and signaling, immunology and vaccination, molecular imaging, current clinical trials and new pharmaceutical developments. Abstract and poster presentations were also part of the conference, as was the annual recognition of a scientist who has achieved prominence in the field of neuroendocrine tumor research.
This year's award went to Dame Julia Polak of London.
The 2nd Annual ENETS Educational Conference was held in Cracow, Poland, 20-22 April 2005.
This conference included lectures on the diagnosis and treatment of neuroendocrine tumors and was attended by nearly 500 researchers and practicing physicians representing 40 countries. The conference was made possible through a generous educational grant from Novartis AG.
The First International Patient Day for Patients with Neuroendocrine Tumor Disease was held at Charite University Hospital, in Berlin, Germany on 20 November 2004.
For a summary of the event and photos, please click on the link below or refer to the Patient's Page.
In March 2004, the 1st Annual ENETS Educational Conference, which was made possible through a generous educational grant from Novartis, was held in Budapest, Hungary.
The conference, titled "Current Status of the Diagnosis and Treatment of Hereditary and Sporadic Neuroendocrine Tumors of the Gastroenteropancreatic System," attracted nearly 350 participants from more than a dozen European countries, Russia and the U.S.